On September 25, 2025, CB Biotechnology, LLC, an affiliate of Future Pak, LLC, completed its acquisition of Theratechnologies Inc., a commercial-stage biopharmaceutical company, by way of a plan of arrangement under the provisions of the Québec Business Corporations Act.
Under the terms of the arrangement, Future Pak LLC’s affiliate has acquired all issued and outstanding common shares of Theratechnologies Inc. for US$3.01 per share in cash plus one contingent value right (“CVR”) per share for additional aggregate cash payments of up to US$1.19 per CVR if certain milestones are achieved, for a total transaction consideration of US$254 million, assuming full payment of the CVRs.
As a result of the completion of the arrangement, the common shares of Theratechnologies Inc. were de-listed from the Toronto Stock Exchange and from the Nasdaq.
A Fasken team composed of Marie-Josée Neveu, Jean-Pierre Chamberland, Monica Dingle, Geneviève Richard and Damien Hallé-Hannan (Securities and M&A), Justine Benoit (Tax), Angela Onesi, Alexandre Gagnon and Marilie Gagné (Banking & Finance), Antonio Di Domenico (Competition and Antitrust), Brandon Farber and Hugo Séguin (Court Proceedings) advised Theratechnologies Inc. in this transaction.
Jurisdiction
- Québec
